Clinical trials: Endocrine System Disorder
Amputation, Diabetes Mellitus, Type 2
Physical Activity Behavior Change for Older Adults After Dysvascular Amputation
This pilot study will use mobile-health technology to deliver an intervention designed for lasting physical activity behavior change.
- Conditions
- Amputation, Diabetes Mellitus, Type 2, Peripheral Artery Disease
- Trial name
- PABC (NCT02738086)
- Testing
- Physical Activity Behavior Change (PABC)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- VA Office of Research and Development
Ischemic Stroke, Hyperglycemia
Procoagulant Effects of Hyperglycemia After Acute Stroke: A Pilot Study
Between twenty and fifty percent of people who have acute stroke have hyperglycemia (high blood sugar) with it. The purpose of this study is to examine the relationships between diabetes mellitus, hyperglycemia,whole blood tissue…
- Trial name
- NCT00373269
- Volunteers
- 21 people
- Sponsor
- Temple University
Metabolic Diseases, Endocrine System Diseases
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
The overall objective of LUCHAR Specific Aims 4.1 and 4.2 is to assess the additional contribution of cardiovascular disease (CVD) risk markers to traditional biomedical risk factors in the prediction of pre-clinical CVD.
- Conditions
- Metabolic Diseases, Endocrine System Diseases, Heart Disease, Vascular Diseases
- Trial name
- NCT00935766
- Testing
- Omega-3
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Denver Health and Hospital Authority
Diabetes Mellitus, Type 2
Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet
The data from this study will be used to compare the kinetic profile of metformin 500mg in linagliptin/metformin fixed dose combination tablet versus Canadian metformin reference product administered concomitantly with…
- Trial name
- NCT01383356
- Testing
- Metformin Single Tablet, Linagliptin/Metformin Combo, Linagliptin Single Tablet
- Where
- Canada
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Turner Syndrome
Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome
This is an extension study that will gather long-term data on the effect of early growth hormone (GH) treatment on adult height and other aspects of health and development in girls with Turner syndrome.
- Trial name
- NCT00266656
- Testing
- Humatrope
- Where
- 9 sites in United States
- Volunteers
- 69 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes
The prevalence of type 2 diabetes (T2D) continues to increase in the US, with 26.8 million adults carrying a diagnosis. Importantly, T2D is widespread in the Veteran population.
- Trial name
- NCT05205005
- Testing
- Endocalyx
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- VA Office of Research and Development
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
The study consists of a retrospective observational, multicenter study in which the fundamental exposure factor being investigated is a drug (rucaparib).
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04539327
- Testing
- Rucaparib
- Where
- 23 sites in Spain
- Volunteers
- 51 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Diabetes, Diabetes Mellitus, Type 2
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Africa, Asia, Europe, North America and South America. The purpose is to compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve…
- Trial name
- DUAL™ VIII (NCT02501161)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 143 sites in United States, Argentina and 14 more
- Volunteers
- 1,012 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Coronary Heart Disease
Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to examine the existence of heart abnormalities in patients with diabetes and the effect of pioglitazone in correcting these abnormalities.
- Trial name
- NCT01588470
- Testing
- pioglitazone
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Breast Carcinoma, Cervical Carcinoma
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer.
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal
- Trial name
- NCT03180294
- Testing
- Bupropion 150 mg XL
- Where
- 362 sites in United States
- Volunteers
- 230 people
- Sponsor
- NRG Oncology
Diabetes Mellitus, Diabetic Peripheral Neuropathy
Immunonutrition for Diabetic Foot Ulcers
Diabetes-induced peripheral neuropathy can lead to the development of diabetic foot ulcers (DFUs), which can have a devastating effect on patients' lives and can lead to life threatening infection, amputations, and even death.
- Conditions
- Diabetes Mellitus, Diabetic Peripheral Neuropathy, Diabetic Foot Ulcer
- Trial name
- NCT05281562
- Testing
- Lovaza, L-Arginine Powder, Vitamin C
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Prisma Health-Midlands
Type 1 Diabetes
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)
To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (based on change in HbA1c from baseline to 24 weeks) when administered in combination with mealtime insulin lispro.
- Trial name
- INSTRIDE 1 (NCT02227862)
- Testing
- Mylan's insulin glargine, Lantus®
- Where
- 162 sites in United States, Canada and 9 more
- Volunteers
- 558 people
- Sponsor
- Mylan Inc.
Diabetes Mellitus, Type 1
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes
This study is being done to find out the good and bad effects of a drug that is not approved for sale and the effects if any on measures of pulmonary function in adult males and females with type 1 diabetes mellitus.
- Trial name
- NCT00137046
- Testing
- Subcutaneous Insulin, Inhaled Insulin
- Where
- 73 sites in United States, Argentina and 3 more
- Volunteers
- 582 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
STOP-T1D Low-Dose (ATG)
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
- Trial name
- TN28 (NCT04291703)
- Testing
- Antithymocyte Globulin
- Where
- 22 sites in United States, Australia
- Volunteers
- 2 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes, Impaired Renal Function
Linagliptin's Effect on CD34+ Stem Cells
Type 2 diabetes is a national epidemic. Diabetes has undesirable effects on blood vessels which may contribute to heart disease. Endothelial Progenitor Cells (EPCs) are found in the blood.
- Trial name
- NCT02467478
- Testing
- Linagliptin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- George Washington University
Ovarian Cancer
Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer
This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of DTA-H19 administered intraperitoneally (IP) in subjects with advanced stage ovarian cancer, or primary peritoneal…
- Trial name
- NCT00826150
- Testing
- BC-819
- Where
- 4 sites in Israel
- Volunteers
- 14 people
- Sponsor
- Anchiano Therapeutics Israel Ltd.
Hyperprolactinemia, Prolactinoma
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist ropinirole for the treatment of hyperprolactinemia in patients with idiopathic hyperprolactinemia and prolactinomas.
- Trial name
- NCT03038308
- Testing
- Ropinirole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University
Ovarian Failure, Premature
Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure
To directly compare the safety (by laboratory evaluation) and efficacy (feminization and growth) of three commonly used estrogen preparations in adolescent patients with ovarian failure, either due to congenital causes (Turner…
- Trial name
- NCT01023178
- Testing
- 17beta Estradiol, Conjugated estrogens, 17Beta Estradiol - transdermal
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Diabetes Mellitus, Type 1, Type 1 Diabetes
Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings
The primary objective of this trial is to determine whether insulin glargine reduces the risk of serious hypoglycemia or improves Time in Range at 6 months when compared against standard of care human insulin (e.g.
- Trial name
- HumAn-1 (NCT05614089)
- Testing
- Insulin Glargine, NPH or premixed 70/30 (human insulin)
- Where
- 3 sites in Bangladesh, Tanzania
- Volunteers
- 400 people
- Sponsor
- Jing Luo
Ketosis, Type 2 Diabetes
Exogenous Ketones in Type 2 Diabetes
Exogenous ketone supplements are proposed to have glucose-lowering potential, provide an alternative fuel for the brain and to enhance cognitive function.
- Trial name
- NCT04194450
- Testing
- Ketone monoester
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- University of British Columbia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.